Insulet Corp
Отворен
СекторЗдравеопазване
147.13 -0.35
Преглед
Промяна на цената на акция
24 ч
Минимум
146.07
Максимум
149.3
Приходи | -11M 91M |
|---|---|
Продажби | -22M 762M |
P/E Средно за сектора | 35.482 49.052 |
EPS | 1.3 |
Марж на печалбата | 11.96 |
Служители | 5,400 |
EBITDA | -23M 154M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +53.21% upside |
Следващи печалби | 6.08.2026 г. |
|---|
Пазарна капитализация | -1.4B 10B |
|---|---|
Предишно отваряне | 147.48 |
Предишно затваряне | 147.13 |
Настроения в новините
By Acuity
68%
32%
306 / 342 Класиране в Healthcare
Insulet Corp Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.